BIOmarkers of Dyspnea IN Emergency Room

Completed

• Conditions: CAPD; Acute Heart Failure; Pulmonary Embolism; Severe Dyspnea; AE COPD

• Registration Number: NCT01227317
• Lead Sponsor: ThermoFisher Scientific Brahms Biomarkers France

Brief Summary

The purpose of this study is to evaluate the capacity of some novels biomarkers Procalcitonin (PCT), Midregional Proadrenomedullin (MR pro ADM), Midregional pro-atrial natriuretic peptide (MR pro ANP), Copeptin (CT pro arginine vasopressin), Pro endothelin to stratify the risk in severe dyspnea.

Detailed Description

In emergency department shortness of breath (SOB)is a common symptom and its cause is not easy to be identified. The risk stratifying remains a challenge, Prognostic value of biomarkers might be helpful.

Study Timeline

• Study Start: 2010-04
• Study First Submitted: 2010-10-21
• Study First Submitted QC: 2010-10-22
• Study First Posted: 2010-10-25
• Primary Completion: 2011-08
• Study Completion: 2011-09
• Status Verified: 2011-12
• Last Update Submitted: 2011-12-06
• Last Update Posted: 2011-12-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 444

Inclusion Criteria

• tachypnea > 25 /min or Pa02 < 70 mmHg or SpO2 < 93%
• diagnosis suspected: CAP, PE,EACOPD, AHF

Exclusion Criteria

• other cause of dyspnea,
• unreachable on Day 30

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
prognostic value of PCT, MR proADM, Mr pro ANP, Copeptin and pro endothelin in SOB	at Day 30	all cause mortality or Intensive Care Unit(ICU) admission from inclusion to Day 30

Secondary Outcome Measures

Name	Time	Method
establish the diagnostic value of PCT and MR pro ANP	at admission	Confirm the diagnostic value of PCT and it's level in sepsis and MR pro ANP in Heart failure

Trial Locations

Locations (1)

Emergency department of Pitié Salpetriere Hospital; 🇫🇷 Paris, France